Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
FDA warns of higher death risk with Pepaxto in multiple myeloma
The FDA also hinted at “a future public meeting to discuss the safety findings and explore the continued marketing of Pepaxto,” which has a price...
News
Latest FDA pembrolizumab approval expands label to cutaneous SCCs
The objective response rate in 54 patients with locally advanced disease was 50%, including a complete response rate of 17% and a partial response...
News
CDC notes sharp declines in breast and cervical cancer screening
The new data come from the National Breast and Cervical Cancer Early Detection Program, which provides cancer screening services to women with low...
News
EC approves cemiplimab for advanced or metastatic BCC after HHI therapy
Cemiplimab immunotherapy is now approved in the European Union and the United States for certain BCCs, CSCCs, and NSCLCs.
News
Rapid update to ASCO breast cancer guidelines after OlympiA data
The American Society of Clinical Oncology (ASCO) now recommends offering 1 year of adjuvant...
News
DCIS: Biosignature helps guide postlumpectomy decisions
The tool shows promise for identifying those whose cancer is likely to recur despite undergoing postlumpectomy radiotherapy.
News
Poloxamer 188 disappoints for painful SCD vaso-occlusive episodes, study showsteaser
Findings from a phase 3 trial failed to support those from a prior study showing that poloxamer 188 shortened painful vaso-occlusive episodes in...
News
FDA approves frontline immunotherapy for gastric cancers
Nivolumab is now approved for the frontline treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal...